GlassScriptPhysician profile
Yelena Chuzhin
NPI 1881691707
$5,816.45
in general payments reported to CMS, 2019-2025
24 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $466 · 2021: $755 · 2022: $899 · 2023: $906 · 2024: $825 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,463.64 |
| Education | $383.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,518.90 | 2019-2025 | Evenity, Enbrel, Prolia |
| Janssen Biotech, INC. | $1,131.73 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $831.92 | 2021-2025 | Saphnelo |
| Abbvie INC. | $525.86 | 2019-2025 | Rinvoq, Humira |
| Radius Health, INC. | $392.72 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $269.85 | 2019-2024 | Benlysta |
| Novartis Pharmaceuticals Corporation | $231.90 | 2019-2023 | |
| Genentech USA, INC. | $196.11 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $154.62 | 2019-2021 | |
| Pfizer INC. | $86.02 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $76.17 | 2022-2025 | Strensiq |
| Alvogen INC | $59.49 | 2024-2025 | Teriparatide |
| Ucb, INC. | $46.66 | 2024-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $42.96 | 2021-2022 | |
| Genzyme Corporation | $42.46 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $39.14 | 2024 | Idacio |
| Fidia Pharma USA INC. | $37.29 | 2020 | |
| Pacira Therapeutics, INC. | $36.21 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $23.66 | 2020 | |
| Mallinckrodt Hospital Products INC. | $15.00 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.82 | 2021 | |
| Sobi, INC | $14.61 | 2024 | |
| Lilly USA, LLC | $14.22 | 2022 | |
| Horizon Therapeutics Plc | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelena Chuzhin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.